For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Intellia Therapeutics Inc’s stock clocked out at $9.00, up 3.45% from its previous closing price of $8.70. In other words, the price has increased by $3.45 from its previous closing price. On the day, 3.67 million shares were traded. NTLA stock price reached its highest trading level at $9.075 during the session, while it also had its lowest trading level at $8.5.
Ratios:
To gain a deeper understanding of NTLA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.77 and its Current Ratio is at 5.77. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 05, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On February 28, 2025, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $45 to $13.
Goldman Downgraded its Neutral to Sell on February 28, 2025, while the target price for the stock was maintained at $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’25 when Clark Eliana sold 679 shares for $8.99 per share. The transaction valued at 6,104 led to the insider holds 95,369 shares of the business.
BASTA JAMES sold 2,572 shares of NTLA for $23,122 on Mar 04 ’25. The EVP, General Counsel now owns 111,925 shares after completing the transaction at $8.99 per share. On Jan 29 ’25, another insider, Bhanji Muna, who serves as the Director of the company, sold 265 shares for $9.97 each. As a result, the insider received 2,642 and left with 19,468 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 931652992 and an Enterprise Value of 540340160. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.10 while its Price-to-Book (P/B) ratio in mrq is 1.05. Its current Enterprise Value per Revenue stands at 9.336 whereas that against EBITDA is -1.031.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.15, which has changed by -0.6645546 over the last 52 weeks, in comparison to a change of 0.086116076 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.54, while it has fallen to a 52-week low of $8.30. The 50-Day Moving Average of the stock is -11.15%, while the 200-Day Moving Average is calculated to be -48.01%.
Shares Statistics:
It appears that NTLA traded 3.14M shares on average per day over the past three months and 2813190 shares per day over the past ten days. A total of 102.03M shares are outstanding, with a floating share count of 97.42M. Insiders hold about 5.89% of the company’s shares, while institutions hold 90.12% stake in the company. Shares short for NTLA as of 1740700800 were 26035739 with a Short Ratio of 8.30, compared to 1738281600 on 24057390. Therefore, it implies a Short% of Shares Outstanding of 26035739 and a Short% of Float of 28.58.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
